COMPARE · Data as of August 12, 2026
ALNY vs GENB
Verdict: Side-by-side breakdown using the Bull Rankings model. ALNY scored 75.4, GENB scored 25.7 — ALNY leads.
Compare another set
ALNY
Alnylam Pharmaceuticals, Inc.
75.4
$223.95 · $30.0B
fundamentals as of
Score gap
49.7
ALNY leads
GENB
Generate Biomedicines, Inc.
25.7
$15.09 · $1.9B
fundamentals as of
The model, pillar by pillar (0–100 each)
ALNY
stronger →← stronger
GENB
67
Qualityreturns · margins · balance sheet
34
100
Growthrevenue & earnings expansion
100
64
Valuevaluation vs sector peers
2
ALNY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ALNY
GENB
$465mC
FCF
-$246mF
+65.2%A
Rev
+55.9%A
2.21D
D/E
0.14B+
38.6xC
P/E
—
0.41A
PEG
—
—
P/S
73.1xD
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ALNY
GENB
174% above
Price vs fair valuelower is cheaper
—
~42%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
-72%
1-yr DCF upside
—
-64%
5-yr DCF upside
—
-46%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ALNY
Why this score
- Diluting shareholders
GENB
Why this score
- Short track record
The companies
ALNYAlnylam Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $30.0b. Down 55% from 52-week high of $495.55 — deep drawdown territory. Revenue growing +65% — in hypergrowth territory. PEG 0.41 — paying under fair value for the growth rate. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $375.76 (implying +68% upside).
Moat
Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 54% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.21 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 55% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 39x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
GENBGenerate Biomedicines, Inc.
Why now
Biotechnology · market cap $1.9b. 17% off the 52-week high of $18.18. Revenue growing +56% — in hypergrowth territory. 5 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $25.60 (implying +70% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$246m) — capital raises or debt issuance likely required; dilution / leverage risk. P/S 73.1x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ALNY and GENB diverge
On the headline score the gap is 49.7 points in favour of ALNY. The widest single difference is Value, where ALNY leads by 61.8 points.
- ValueALNY 64.1 · GENB 2.3ALNY +61.8
- QualityALNY 66.8 · GENB 33.9ALNY +32.9
- GrowthALNY 100.0 · GENB 100.0level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.